Table of contents


Please note that this product was withdrawn from the Community register of designated orphan medicinal products in February 2013 on request of the sponsor.

On 20 October 2004, orphan designation (EU/3/04/231) was granted by the European Commission to Neuraxo Biopharmaceuticals GmbH, Germany, for deferoxamine mesilate for the treatment of traumatic spinal-cord injury.

Neuraxo Biopharmaceuticals GmbH changed name to SCT Spinal Cord Therapeutics GmbH in May 2009.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
Deferoxamine mesilate
Disease / condition
Treatment of traumatic spinal cord injury
Date of first decision
EU designation number

Sponsor's contact details

SCT Spinal Cord Therapeutics GmbH
Max-Planck-Straße 15a
D-40699 Erkrath
Tel. +49 211 617851 0
Fax +49 211 617851 50

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating